About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 759760, 13 pages
http://dx.doi.org/10.1155/2013/759760
Review Article

The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis

Division of Rheumatology, University and IRCCS Foundation Policlinico S. Matteo, Viale Golgi 3, 27100 Pavia, Italy

Received 21 May 2013; Revised 15 August 2013; Accepted 20 August 2013

Academic Editor: Carlo Jose Freire de Oliveira

Copyright © 2013 Lorenzo Cavagna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Montecucco, L. Cavagna, and R. Caporali, “Pain and rheumatology: an overview of the problem,” European Journal of Pain Supplements, vol. 3, no. 2, pp. 105–109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Caporali, L. Cavagna, and C. Montecucco, “Pain in arthritis,” European Journal of Pain Supplements, vol. 3, no. 2, pp. 123–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Govoni and R. Caporali, “Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand?” Clinical and Experimental Rheumatology, vol. 30, no. 4, pp. 459–463, 2012.
  4. E. Krishnan, B. Lingala, B. Bruce, and J. F. Fries, “Disability in rheumatoid arthritis in the era of biological treatments,” Annals of the Rheumatic Diseases, vol. 71, no. 2, pp. 213–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. E. Gabriel, C. S. Crowson, H. M. Kremers et al., “Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years,” Arthritis and Rheumatism, vol. 48, no. 1, pp. 54–58, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Cimmino, C. Salvarani, P. Macchioni et al., “Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis,” Rheumatology International, vol. 19, no. 6, pp. 213–217, 2000. View at Scopus
  7. L. Cavagna, N. Boffini, G. Cagnotto, F. Inverardi, V. Grosso, and R. Caporali, “Atherosclerosis and rheumatoid arthritis: more than a simple association,” Mediators of Inflammation, vol. 2012, Article ID 147354, 8 pages, 2012. View at Publisher · View at Google Scholar
  8. C. Turesson, “Extra-articular rheumatoid arthritis,” Current Opinion in Rheumatology, vol. 25, no. 3, pp. 360–366, 2013. View at Publisher · View at Google Scholar
  9. U. A. Gauhar, A. L. Gaffo, and G. S. Alarcón, “Pulmonary manifestations of rheumatoid arthritis,” Seminars in Respiratory and Critical Care Medicine, vol. 28, no. 4, pp. 430–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. de Lauretis, S. Veeraraghavan, and E. Renzoni, “Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?” Chronic Respiratory Disease, vol. 8, no. 1, pp. 53–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Ellman and R. E. Ball, “Rheumatoid arthritis with joint and pulmonary manifestations,” The British Journal of Medicine, vol. 2, no. 4583, pp. 816–820, 1948. View at Publisher · View at Google Scholar
  12. E. H. Rubin, “Pulmonary lesions in “rheumatoid disease” with remarks on diffuse interstitial pulmonary fibrosis,” The American Journal of Medicine, vol. 19, no. 4, pp. 569–582, 1955. View at Scopus
  13. E. J. Kim, B. M. Elicker, F. Maldonado et al., “Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease,” European Respiratory Journal, vol. 35, no. 6, pp. 1322–1328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. D. P. Ascherman, “Interstitial lung disease in rheumatoid arthritis,” Current Rheumatology Reports, vol. 12, no. 5, pp. 363–369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. G. W. Hunninghake and A. S. Fauci, “Pulmonary involvement in the collagen vascular diseases,” The American Review of Respiratory Disease, vol. 119, no. 3, pp. 471–503, 1979. View at Scopus
  16. P. Cervantes-Perez, A. H. Toro-Perez, and P. Rodriguez-Jurado, “Pulmonary involvement in rheumatoid arthritis,” The Journal of the American Medical Association, vol. 243, no. 17, pp. 1715–1719, 1980. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Koduri, S. Norton, A. Young et al., “Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort,” Rheumatology, vol. 49, no. 8, Article ID keq035, pp. 1483–1489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Young and G. Koduri, “Extra-articular manifestations and complications of rheumatoid arthritis,” Best Practice and Research: Clinical Rheumatology, vol. 21, no. 5, pp. 907–927, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Bongartz, C. Nannini, Y. F. Medina-Velasquez et al., “Incidence and mortality of interstitial lung disease in rheumatoid arthritis—a population-based study,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1583–1591, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Cavagna, R. Caporali, L. Abdì-Alì, R. Dore, F. Meloni, and C. Montecucco, “Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease,” Journal of Rheumatology, vol. 40, no. 4, pp. 484–492, 2013. View at Publisher · View at Google Scholar
  21. L. M. Nogee, A. E. Dunbar, S. E. Wert, F. Askin, A. Hamvas, and J. A. Whitsett, “A mutation in the surfactant protein C gene associated with familial interstitial lung disease,” The New England Journal of Medicine, vol. 344, no. 8, pp. 573–579, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. J. C. Grutters and R. M. du Bois, “Genetics of fibrosing lung diseases,” European Respiratory Journal, vol. 25, no. 5, pp. 915–927, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Mori, Y. Koga, and M. Sugimoto, “Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis,” Respiratory Medicine, vol. 106, no. 11, pp. 1591–1599, 2012. View at Publisher · View at Google Scholar
  24. K.G. Saag, S. Kolluri, R. K. Koehnke, et al., “Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities,” Arthritis and Rheumatism, vol. 39, no. 10, pp. 1711–1719, 1996.
  25. M. Toyoshima, K. Chida, T. Suda, and M. Sato, “Methotrexate might increase mortality from interstitial lung disease in rheumatoid arthritis,” The American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 9, p. 1024, 2012. View at Scopus
  26. S. Inokuma, “Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury,” Expert Opinion on Drug Safety, vol. 10, no. 4, pp. 603–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Perez-Alvarez, M. Perez-de-Lis, C. Diaz-Lagares et al., “Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases,” Seminars in Arthritis and Rheumatism, vol. 41, no. 2, pp. 256–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. S. T. Panopoulos and P. P. Sfikakis, “Biological treatments and connective tissue disease associated interstitial lung disease,” Current Opinion in Pulmonary Medicine, vol. 17, no. 5, pp. 362–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Agustí, “American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonia,” The American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 2, pp. 277–304, 2002. View at Scopus
  30. Y. Tsuchiya, N. Takayanagi, H. Sugiura et al., “Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome,” European Respiratory Journal, vol. 37, no. 6, pp. 1411–1417, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. H. K. Lee, D. S. Kim, B. Y. Yoo et al., “Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease,” Chest, vol. 127, no. 6, pp. 2019–2027, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. C. Manjunatha, A. Seith, H. Kandpal, and C. J. Das, “Rheumatoid arthritis: spectrum of computed tomographic findings in pulmonary diseases,” Current Problems in Diagnostic Radiology, vol. 39, no. 6, pp. 235–246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Gutsche, G. D. Rosen, and J. J. Swigris, “Connective tissue disease-associated interstitial lung disease: a review,” Current Respiratory Care Reports, vol. 1, no. 4, pp. 224–232, 2012. View at Publisher · View at Google Scholar
  34. S. N. Mink and B. Maycher, “Comparative manifestations and diagnostic accuracy of high-resolution computed tomography in usual interstitial pneumonia and nonspecific interstitial pneumonia,” Current Opinion in Pulmonary Medicine, vol. 18, no. 5, pp. 530–534, 2012. View at Publisher · View at Google Scholar
  35. N. C. Richman, J. Yazdany, J. Graf, V. Chernitskiy, and J. B. Imboden, “Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients,” Medicine, vol. 92, no. 2, pp. 92–97, 2013. View at Publisher · View at Google Scholar
  36. E. Myasoedova, C. S. Crowson, C. Turesson, S. E. Gabriel, and E. L. Matteson, “Incidence of extraarticular rheumatoid arthritis in olmsted county, Minnesota, in 1995–2007 versus 1985–1994: a population-based study,” Journal of Rheumatology, vol. 38, no. 6, pp. 983–989, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. C. M. Bartels, C. L. Bell, K. Shinki, A. Rosenthal, and A. J. Bridges, “Changing trends in serious extra-articular manifestations of rheumatoid arthritis among united state veterans over 20 years,” Rheumatology, vol. 49, no. 9, Article ID keq135, pp. 1670–1675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. H. M. Habib, A. A. Eisa, W. R. Arafat, and M. A. Marie, “Pulmonary involvement in early rheumatoid arthritis patients,” Clinical Rheumatology, vol. 30, no. 2, pp. 217–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. L. Olson, J. J. Swigris, D. B. Sprunger et al., “Rheumatoid arthritis-interstitial lung disease-associated mortality,” The American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 3, pp. 372–378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. J. Hamblin and M. R. Horton, “Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma,” Pulmonary Medicine, vol. 2011, Article ID 872120, 12 pages, 2011. View at Publisher · View at Google Scholar
  41. A. Young, G. Koduri, M. Batley et al., “Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis,” Rheumatology, vol. 46, no. 2, pp. 350–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. E. A. Khan, L. K. Stamp, J. L. O’Donnell , and P. T. Chapman, “Cardiovascular morbidity in rheumatoid arthritis patients in North Canterbury, New Zealand 1999–2008,” International Journal of Rheumatic Diseases, vol. 16, no. 1, pp. 19–23, 2013.
  43. P. Stolt, H. Källberg, I. Lundberg, B. Sjögren, L. Klareskog, and L. Alfredsson, “Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study,” Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. 582–586, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Caplan, “Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis,” Thorax, vol. 8, no. 1, pp. 29–37, 1953. View at Scopus
  45. J. Schreiber, D. Koschel, J. Kekow, N. Waldburg, A. Goette, and R. Merget, “Rheumatoid pneumoconiosis (Caplan's syndrome),” European Journal of Internal Medicine, vol. 21, no. 3, pp. 168–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. R. A. C. Cohen, A. Patel, and F. H. Y. Green, “Lung disease caused by exposure to coal mine and silica dust,” Seminars in Respiratory and Critical Care Medicine, vol. 29, no. 6, pp. 651–661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Yahya, C. Bengtsson, T. C. Lai et al., “Smoking is associated with an increased risk of developing ACPA-positive but not ACPA-negative rheumatoid arthritis in Asian populations: evidence from the Malaysian MyEIRA case-control study,” Modern Rheumatology, vol. 22, no. 4, pp. 524–531, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. T. R. Mikuls, H. Sayles, F. Yu et al., “Associations of cigarette smoking with rheumatoid arthritis in African Americans,” Arthritis and Rheumatism, vol. 62, no. 12, pp. 3560–3568, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Hutchinson, L. Shepstone, R. Moots, J. T. Lear, and M. P. Lynch, “Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA,” Annals of the Rheumatic Diseases, vol. 60, no. 3, pp. 223–227, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. A. J. Thorley and T. D. Tetley, “Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease,” International Journal of Chronic Obstructive Pulmonary Diseases, vol. 2, no. 4, pp. 409–428, 2007. View at Scopus
  51. B. Balbi, V. Cottin, S. Singh, W. de Wever, F. J. F. Herth, and C. Robalo Cordeiro, “Smoking-related lung diseases: a clinical perspective,” European Respiratory Journal, vol. 35, no. 2, pp. 231–233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Vassallo and J. H. Ryu, “Smoking-related interstitial lung diseases,” Clinics in Chest Medicine, vol. 33, no. 1, pp. 165–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. M. L. Westedt, J. M. W. Hazes, F. C. Breedveld, P. J. Sterk, and J. H. Dijkman, “Cigarette smoking and pulmonary diffusion defects in rheumatoid arthritis,” Rheumatology International, vol. 18, no. 1, pp. 1–4, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. K. G. Saag, S. Kolluri, R. K. Koehnke et al., “Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities,” Arthritis and Rheumatism, vol. 39, no. 10, pp. 1711–1719, 1996. View at Scopus
  55. B. R. Gochuico, N. A. Avila, C. K. Chow et al., “Progressive preclinical interstitial lung disease in rheumatoid arthritis,” Archives of Internal Medicine, vol. 168, no. 2, pp. 159–166, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Sakaida, “IgG rheumatoid factor in rheumatoid arthritis with interstitial lung disease,” Ryumachi, vol. 35, no. 4, pp. 671–677, 1995. View at Scopus
  57. I. Alexiou, A. Germenis, A. Koutroumpas, A. Kontogianni, K. Theodoridou, and L. I. Sakkas, “Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 27, no. 4, pp. 511–513, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Aubart, B. Crestani, P. Nicaise-Roland et al., “High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis,” Journal of Rheumatology, vol. 38, no. 6, pp. 979–982, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Inui, N. Enomoto, T. Suda, Y. Kageyama, H. Watanabe, and K. Chida, “Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis,” Clinical Biochemistry, vol. 41, no. 13, pp. 1074–1077, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Fischer, J. J. Solomon, R. M. du Bois et al., “Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease,” Respiratory Medicine, vol. 106, no. 7, pp. 1040–1047, 2012. View at Publisher · View at Google Scholar
  61. A. M. Gizinski, M. Mascolo, J. L. Loucks et al., “Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA,” Clinical Rheumatology, vol. 28, no. 5, pp. 611–613, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Bongartz, T. Cantaert, S. R. Atkins et al., “Citrullination in extra-articular manifestations of rheumatoid arthritis,” Rheumatology, vol. 46, no. 1, pp. 70–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Harlow, I. O. Rosas, B. R. Gochuico et al., “Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease,” Arthritis and Rheumatisms, vol. 65, no. 4, pp. 869–879, 2013. View at Publisher · View at Google Scholar
  64. L. Klareskog, V. Malmström, K. Lundberg, L. Padyukov, and L. Alfredsson, “Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis,” Seminars in Immunology, vol. 23, no. 2, pp. 92–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Migita, T. Nakamura, T. Koga, and K. Eguchi, “HLA-DRB1 alleles and rheumatoid arthritis-related pulmonary fibrosis,” Journal of Rheumatology, vol. 37, no. 1, pp. 205–207, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Furukawa, S. Oka, K. Shimada et al., “Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope,” PLoS ONE, vol. 7, no. 5, Article ID e33133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. J. D. Gorman, R. F. Lum, J. J. Chen, M. E. Suarez-Almazor, G. Thomson, and L. A. Criswell, “Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 400–412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. J. D. Gorman, E. David-Vaudey, M. Pai, R. F. Lum, and L. A. Criswell, “Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis,” Arthritis and Rheumatism, vol. 50, no. 11, pp. 3476–3484, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Santiago-Casas, T. C. González-Rivera, L. E. Castro-Santana et al., “Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis,” Ethnicity and Disease, vol. 20, supplement 1, pp. S1–S191, 2010. View at Scopus
  70. C. Turesson, W. M. O'Fallon, C. S. Crowson, S. E. Gabriel, and E. L. Matteson, “Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years,” Annals of the Rheumatic Diseases, vol. 62, no. 8, pp. 722–727, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. V. Saravanan and C. Kelly, “Drug-related pulmonary problems in patients with rheumatoid arthritis,” Rheumatology, vol. 45, no. 7, pp. 787–789, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Furukawa, S. Oka, K. Shimada, Rheumatoid Arthritis-Interstitial Lung Disease Study Consortium, N. Tsuchiya, and S. Tohma, “HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker?” Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 153–155, 2013.
  73. K. Shidara, D. Hoshi, E. Inoue et al., “Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA,” Modern Rheumatology, vol. 20, no. 3, pp. 280–286, 2010. View at Scopus
  74. S. R. Jordan, V. R. Stevanovic, P. Herbison, J. Dockerty, and J. Highton, “Methotrexate pneumonitis in rheumatoid arthritis: increased prevalence with increasing latitude: an epidemiological study of trends in New Zealand,” Journal of Clinical Rheumatology, vol. 17, no. 7, pp. 356–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. G. J. Carroll, R. Thomas, C. C. Phatouros et al., “Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate,” Journal of Rheumatology, vol. 21, no. 1, pp. 51–54, 1994. View at Scopus
  76. J. H. Ju, S. I. Kim, J. H. Lee et al., “Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 56, no. 6, pp. 2094–2096, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Chikura, S. Lane, and J. K. Dawson, “Clinical expression of leflunomide-induced pneumonitis,” Rheumatology, vol. 48, no. 9, pp. 1065–1068, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Sawada, S. Inokuma, T. Sato et al., “Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis,” Rheumatology, vol. 48, no. 9, pp. 1069–1072, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Martin, J. A. Innes, C. M. Lambert, C. M. Turnbull, and W. A. H. Wallace, “Hypersensitivity pneumonitis associated with leflunomide therapy,” Journal of Rheumatology, vol. 34, no. 9, pp. 1934–1937, 2007. View at Scopus
  80. T. Namba, K.-. Tanaka, Y. Ito et al., “Induction of EMT-like phenotypes by an active metabolite of leflunomide and its contribution to pulmonary fibrosis,” Cell Death and Differentiation, vol. 17, no. 12, pp. 1882–1895, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Hinz, S. H. Phan, V. J. Thannickal, A. Galli, M. Bochaton-Piallat, and G. Gabbiani, “The myofibroblast: one function, multiple origins,” The American Journal of Pathology, vol. 170, no. 6, pp. 1807–1816, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. L. Peno-Green, G. Lluberas, T. Kingsley, and S. Brantley, “Lung injury linked to etanercept therapy,” Chest, vol. 122, no. 5, pp. 1858–1860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Perez-Alvarez, M. Perez-de-Lis, C. Diaz-Lagares et al., “Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases,” Seminars in Arthritis and Rheumatism, vol. 41, no. 2, pp. 256–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Pearce, S. R. Johnson, and P. Courtney, “Interstitial lung disease following certolizumab pegol,” Rheumatology, vol. 51, no. 3, Article ID ker309, pp. 578–580, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Caporali, F. B. Pallavicini, M. Filippini et al., “Treatment of rheumatoid arthritis with anti-TNF-α agents: a reappraisal,” Autoimmunity Reviews, vol. 8, no. 3, pp. 274–280, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. C. Montecucco, R. Caporali, and M. Matucci-Cerinic, “Updating the Italian society for rheumatology recommendations for biologic therapy in adult patients with inflammatory rheumatic diseases,” Clinical and experimental rheumatology, vol. 29, no. 3, supplement 66, pp. S3–S6, 2011. View at Scopus
  87. A. Schuller, M. Coudurier, J. C. Lega, C. Khouatra, V. Cottin, and J. F. Cordier, “Interstitial lung disease and anti-TNF-α therapy in rheumatoid arthritis: two different patterns?” Revue des Maladies Respiratoires, vol. 27, no. 3, pp. 232–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Mori, F. Imamura, C. Kiyofuji, and M. Sugimoto, “Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor α-neutralizing antibody,” Modern Rheumatology, vol. 16, no. 4, pp. 251–255, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. Q. Ye, H. Dai, R. Sarria, J. Guzman, and U. Costabel, “Increased expression of tumor necrosis factor receptors in cryptogenic organizing pneumonia,” Respiratory Medicine, vol. 105, no. 2, pp. 292–297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. E. M. Thomson, A. Williams, C. L. Yauk, and R. Vincent, “Overexpression of tumor necrosis factor-α in the lungs alters immune response, matrix remodeling, and repair and maintenance pathways,” The American Journal of Pathology, vol. 180, no. 4, pp. 1413–1430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Mikami, Y. Yamauchi, M. Horie et al., “Tumor necrosis factor superfamily member LIGHT induces epithelial-mesenchymal transition in A549 human alveolar epithelial cells,” Biochemical Biophysical Research Communication, vol. 428, no. 4, pp. 451–457, 2012. View at Publisher · View at Google Scholar
  92. S. Sen, C. Peltz, K. Jordan, and T. J. Boes, “Infliximab-induced nonspecific interstitial pneumonia,” The American Journal of the Medical Sciences, vol. 344, no. 1, pp. 78–78, 2012. View at Publisher · View at Google Scholar
  93. M. Kuroki, Y. Noguchi, M. Shimono et al., “Repression of bleomycin-induced pneumopathy by TNF,” Journal of Immunology, vol. 170, no. 1, pp. 567–574, 2003. View at Scopus
  94. T. A. Wynn, “Fibrotic disease and the TH1/TH2 paradigm,” Nature Reviews Immunology, vol. 4, no. 8, pp. 583–594, 2004. View at Scopus
  95. M. U. Mirkov, J. Cui, S. H. Vermeulen, et al., “Genomenome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 72, no. 8, pp. 1375–1381, 2013. View at Publisher · View at Google Scholar
  96. F. Ceccarelli, S. D'Alfonso, C. Perricone et al., “The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 30, no. 6, pp. 939–942, 2012.
  97. W. G. Dixon, K. L. Hyrich, K. D. Watson, M. Lunt, and D. P. M. Symmons, “Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British society for rheumatology biologics register,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 1086–1091, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. L. J. Herrinton, L. R. Harrold, L. Liu et al., “Association between anti-TNF-α therapy and interstitial lung disease,” Pharmacoepidemiology and Drug Safety, vol. 22, no. 4, pp. 394–402, 2013. View at Publisher · View at Google Scholar
  99. R. Vassallo, E. Matteson, and C. F. Thomas Jr., “Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-α inhibition,” Chest, vol. 122, no. 3, pp. 1093–1096, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. E. Bargagli, M. Galeazzi, and P. Rottoli, “Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis,” European Respiratory Journal, vol. 24, no. 4, p. 708, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. K. M. Antoniou, M. Mamoulaki, K. Malagari et al., “Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease,” Clinical and Experimental Rheumatology, vol. 25, no. 1, pp. 23–28, 2007. View at Scopus
  102. Y. Wang, S. Q. Xu, J. H. Xu, and C. Ding, “Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease,” Clinical Medicine Insights: Case Reports, vol. 4, pp. 49–52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Horai, T. Miyamura, K. Shimada et al., “Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease,” Journal of Clinical Pharmacy and Therapeutics, vol. 37, no. 1, pp. 117–121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Komiya, H. Ishii, N. Fujita et al., “Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement,” Internal Medicine, vol. 50, no. 7, pp. 749–751, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. S. A. Wagner, A. C. Mehta, and D. A. Laber, “Rituximab-induced interstitial lung disease,” The American Journal of Hematology, vol. 82, no. 10, pp. 916–919, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. R. Ram, I. Ben-Bassat, O. Shpilberg, A. Polliack, and P. Raanani, “The late adverse events of rituximab therapy—rare but there!,” Leukemia and Lymphoma, vol. 50, no. 7, pp. 1083–1095, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. Wu, Y. Jia, J. Xu, X. Shuai, and Y. Wu, “Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature,” Journal of Clinical Pharmacy and Therapeutics, vol. 38, no. 3, pp. 249–253, 2013. View at Publisher · View at Google Scholar
  108. A. J. Thorley and T. D. Tetley, “Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease,” International Journal of Chronic Obstructive Pulmonary Diseases, vol. 2, no. 4, pp. 409–428, 2007. View at Scopus
  109. Q. Yang, M. J. Underwood, M. K. Y. Hsin, X. C. Liu, and G. W. He, “Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development,” Current Drug Metabolism, vol. 9, no. 7, pp. 661–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. Z. Baka, E. Buzás, and G. Nagy, “Rheumatoid arthritis and smoking: putting the pieces together,” Arthritis Research and Therapy, vol. 11, no. 4, p. 238, 2009. View at Scopus
  111. J. D. Mathews, B. M. Hooper, S. Whittingham, I. R. Mackay, and N. S. Stenhouse, “Association of autoantibodies with smoking, cardiovascular morbidity, and death in the Busselton population,” The Lancet, vol. 2, no. 7832, pp. 754–758, 1973. View at Scopus
  112. T. Tuomi, M. Heliovaara, T. Palosuo, and K. Aho, “Smoking, lung function, and rheumatoid factors,” Annals of the Rheumatic Diseases, vol. 49, no. 10, pp. 753–756, 1990. View at Scopus
  113. M. S. Wilson and T. A. Wynn, “Pulmonary fibrosis: pathogenesis, etiology and regulation,” Mucosal Immunology, vol. 2, no. 2, pp. 103–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. S. C. L. Farhat, C. A. Silva, M. A. M. Orione, L. M. A. Campos, A. M. E. Sallum, and A. L. F. Braga, “Air pollution in autoimmune rheumatic diseases: a review,” Autoimmunity Reviews, vol. 11, no. 1, pp. 14–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. S. A. Yousem, T. V. Colby, and C. B. Carrington, “Lung biopsy in rheumatoid arthritis,” The American Review of Respiratory Disease, vol. 131, no. 5, pp. 770–777, 1985. View at Scopus
  116. A. Manzo, B. Vitolo, F. Humby et al., “Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint,” Arthritis and Rheumatism, vol. 58, no. 11, pp. 3377–3387, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. S. R. Atkins, C. Turesson, J. L. Myers et al., “Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia,” Arthritis and Rheumatism, vol. 54, no. 2, pp. 635–641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Turesson, E. L. Matteson, T. V. Colby et al., “Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis,” Arthritis and Rheumatism, vol. 52, no. 1, pp. 73–79, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. Y. Nagasawa, T. Takada, T. Shimizu et al., “Inflammatory cells in lung disease associated with rheumatoid arthritis,” Internal Medicine, vol. 48, no. 14, pp. 1209–1217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. G. Hoser, J. Kawiak, J. Domagała-Kulawik, P. Kopiński, and W. Droszcz, “Flow cytometric evaluation of lymphocyte subpopulations in BALF of healthy smokers and nonsmokers,” Folia Histochemica et Cytobiologica, vol. 37, no. 1, pp. 25–30, 1999. View at Scopus
  121. J. G. N. Garcia, H. L. James, S. Zinkgraf, M. B. Perlman, and B. A. Keogh, “Lower respiratory tract abnormalities in rheumatoid interstitial lung disease. Potential role of neutrophils in lung injury,” The American Review of Respiratory Disease, vol. 136, no. 4, pp. 811–817, 1987. View at Scopus
  122. R. C. Keith, J. L. Powers, E. F. Redente et al., “A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice,” Experimental Lung Research, vol. 38, no. 2, pp. 55–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. K. Zhang, M. Gharaee-Kermani, B. McGarry, D. Remick, and S. H. Phan, “TNF-α-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis,” Journal of Immunology, vol. 158, no. 2, pp. 954–959, 1997. View at Scopus
  124. L. K. A. Lundblad, J. Thompson-Figueroa, T. Leclair et al., “Tumor necrosis factor-α overexpression in lung disease: a single cause behind a complex phenotype,” The American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 12, pp. 1363–1370, 2005. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Vasakova, I. Striz, A. Slavcev et al., “Correlation of IL-1α and IL-4 gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis,” Scandinavian Journal of Immunology, vol. 65, no. 3, pp. 265–270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. J. Rangel-Moreno, L. Hartson, C. Navarro, M. Gaxiola, M. Selman, and T. D. Randall, “Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis,” Journal of Clinical Investigation, vol. 116, no. 12, pp. 3183–3194, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. C. Agostini and C. Gurrieri, “Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis,” Proceedings of the American Thoracic Society, vol. 3, no. 4, pp. 357–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. J. M. Vignaud, M. Allam, N. Martinet, M. Pech, F. Plenat, and Y. Martinet, “Presence of platelet-derived growth factor in normal and fibrotic lung is specifically associated with interstitial macrophages, while both interstitial macrophages and alveolar epithelial cells express the c-sis proto-oncogene,” The American Journal of Respiratory Cell and Molecular Biology, vol. 5, no. 6, pp. 531–538, 1991. View at Scopus
  129. E. J. Battegay, E. W. Raines, T. Colbert, and R. Ross, “TNF-α stimulation of fibroblast proliferation: dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression,” Journal of Immunology, vol. 154, no. 11, pp. 6040–6047, 1995. View at Scopus
  130. A. Abdollahi, M. Li, G. Ping et al., “Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis,” Journal of Experimental Medicine, vol. 201, no. 6, pp. 925–935, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. C. Ramos, M. Montaño, J. García-Alvarez et al., “Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression,” The American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 5, pp. 591–598, 2001. View at Scopus
  132. T. R. Dunkern, D. Feurstein, G. A. Rossi, F. Sabatini, and A. Hatzelmann, “Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase,” European Journal of Pharmacology, vol. 572, no. 1, pp. 12–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. J. K. Dawson, H. E. Fewins, J. Desmond, M. P. Lynch, and D. R. Graham, “Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests,” Thorax, vol. 56, no. 8, pp. 622–627, 2001. View at Publisher · View at Google Scholar · View at Scopus
  134. B. Wallaert, P. Y. Hatron, J. M. Grosbois, A. B. Tonnel, B. Devulder, and C. Voisin, “Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function,” The American Review of Respiratory Disease, vol. 133, no. 4, pp. 574–580, 1986. View at Scopus
  135. F. Salaffi, P. Manganelli, M. Carotti, and S. Baldelli, “The differing patterns of subclinical pulmonary involvement in connective tissue diseases as shown by application of factor analysis,” Clinical Rheumatology, vol. 19, no. 1, pp. 35–41, 2000. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Biederer, A. Schnabel, C. Muhle, W. L. Gross, M. Heller, and M. Reuter, “Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis,” European Radiology, vol. 14, no. 2, pp. 272–280, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. F. Kinoshita, H. Hamano, H. Harada et al., “Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT,” Respiratory Medicine, vol. 98, no. 11, pp. 1131–1137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. T. Oyama, N. Kohno, A. Yokoyama et al., “Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin,” Lung, vol. 175, no. 6, pp. 379–385, 1997. View at Publisher · View at Google Scholar · View at Scopus
  139. S. Horie, K. Nakada, S. Minota, and S. Kano, “High proliferative potential colony-forming cells (HPP-CFCs) in the peripheral blood of rheumatoid arthritis patients with interstitial lung disease,” Scandinavian Journal of Rheumatology, vol. 32, no. 5, pp. 273–276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  140. J. Fujita, N. Dobashi, Y. Ohtsuki et al., “Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders,” Lung, vol. 177, no. 5, pp. 311–319, 1999. View at Publisher · View at Google Scholar · View at Scopus
  141. K. Maniwa, F. Ogushi, K. Tani, Y. Ohmoto, M. Muraguchi, and S. Sone, “Increased incidence of autoantibodies to interleukin-1α in rheumatoid arthritis with interstitial lung disease,” Respirology, vol. 5, no. 4, pp. 315–320, 2000. View at Publisher · View at Google Scholar · View at Scopus
  142. A. L. Mammen, “Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis,” Annals of the New York Academy of Sciences, vol. 1184, pp. 134–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. L. Cavagna, C. Fusetti, C. Montecucco, and R. Caporali, “Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome,” Journal of Rheumatology, vol. 37, no. 9, p. 1967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. Y. Koreeda, I. Higashimoto, M. Yamamoto et al., “Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies,” Internal Medicine, vol. 49, no. 5, pp. 361–369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. R. Stanciu, M. Guiguet, L. Musset et al., “Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use,” Journal of Rheumatology, vol. 39, no. 9, pp. 1835–1839, 2012. View at Publisher · View at Google Scholar
  146. K. Marzouk, L. Corate, S. Saleh, and O. P. Sharma, “Epstein-Barr-virus-induced interstitial lung disease,” Current Opinion in Pulmonary Medicine, vol. 11, no. 5, pp. 456–460, 2005. View at Scopus
  147. C. A. Müller, H. Hebart, A. Roos, H. Roos, M. Steidle, and H. Einsele, “Correlation of interstitial pneumonia with human cytomegalovirus-induced lung infection and graft-versus-host disease after bone marrow transplantation,” Medical Microbiology and Immunology, vol. 184, no. 3, pp. 115–121, 1995. View at Scopus
  148. L. Cavagna and R. Caporali, “Therapeutic options in anti-Jo1 antisynthetase syndrome with interstitial lung disease,” Arthritis Care and Research, vol. 65, no. 9, p. 1548, 2013. View at Publisher · View at Google Scholar
  149. K. M. Antoniou, G. Margaritopoulos, F. Economidou, and N. M. Siafakas, “Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement,” European Respiratory Journal, vol. 33, no. 4, pp. 882–896, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. C. Lamblin, C. Bergoin, T. Saelens, and B. Wallaert, “Interstitial lung diseases in collagen vascular diseases,” European Respiratory Journal Supplement, vol. 18, no. 32, pp. 69–80, 2001. View at Scopus
  151. C. Kelly and V. Saravanan, “Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease,” Expert Opinion on Pharmacotherapy, vol. 9, no. 18, pp. 3221–3230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. L. A. Saketkoo and L. R. Espinoza, “Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug,” Archives of Internal Medicine, vol. 168, no. 15, pp. 1718–1719, 2008. View at Publisher · View at Google Scholar · View at Scopus
  153. M. P. E. Puttick, A. V. Klinkhoff, A. Chalmers, and D. N. Ostrow, “Treatment of progressive rheumatoid interstitial lung disease with cyclosporine,” Journal of Rheumatology, vol. 22, no. 11, pp. 2163–2165, 1995. View at Scopus
  154. D. Ogawa, H. Hashimoto, J. Wada et al., “Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis,” Rheumatology, vol. 39, no. 12, pp. 1422–1424, 2000. View at Scopus
  155. H. K. Chang, W. Park, and D. S. Ryu, “Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report,” Journal of Korean medical science, vol. 17, no. 2, pp. 270–273, 2002. View at Scopus
  156. Z. M. Metafratzi, A. N. Georgiadis, C. V. Ioannidou et al., “Pulmonary involvement in patients with early rheumatoid arthritis,” Scandinavian Journal of Rheumatology, vol. 36, no. 5, pp. 338–344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. J. Rojas-Serrano, E. González-Velásquez, M. Mejía, A. Sánchez-Rodríguez, and G. Carrillo, “Interstitial lung disease related to rheumatoid arthritis: evolution after treatment,” Reumatología Clínica, vol. 8, no. 2, pp. 68–71, 2012. View at Publisher · View at Google Scholar
  158. M. Mohr and A. M. Jacobi, “Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade,” Scandinavian Journal of Rheumatology, vol. 40, no. 5, pp. 400–401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  159. A. V. Hadjinicolaou, M. K. Nisar, S. Bhagat, H. Parfrey, E. R. Chilvers, and A. J. K. Östör, “Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review,” Rheumatology, vol. 50, no. 12, Article ID ker289, pp. 2297–2305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Y. Kawashiri, A. Kawakami, N. Sakamoto, Y. Ishimatsu, and K. Eguchi, “A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab,” Rheumatology International, vol. 32, no. 12, pp. 4023–4026, 2012. View at Publisher · View at Google Scholar · View at Scopus